Kengreal Approved for Use in Adult Patients Undergoing Percutaneous Coronary Intervention
June 22, 2015 - The U.S. Food and Drug Administration (FDA) approved Kengreal (cangrelor for injection), manufactured by The Medicines Company. Kengreal is an intravenous (IV) P2Y12 platelet inhibitor, indicated to reduce the risks of serious clotting complications for adult patients undergoing percutaneous coronary intervention (PCI) which puts patients at risk for myocardial infarction, repeat coronary revascularization and stent thrombosis. Consistent with antiplatelet therapies, the most serious risk of Kengreal is bleeding, which can be life threatening. Kengreal is administered via IV infusion for at least 2 hours or for the duration of the PCI procedure, whichever is longer. A P2Y12 platelet inhibitor, such as Plavix, Effient, or Brilinta should be administered immediately after discontinuation of Kengreal infusion to maintain platelet inhibition. Kengreal should not be administered concurrently with a glycoprotein IIb/IIIa inhibitor, such as ReoPro, Integrilin and Tirofiban. Platelet function returns to normal within 1 hour after discontinuation of Kengreal.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.